Major bleeding · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin probably leads to higher major bleeding compared with no thromboprophylaxis (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with primary hypertension
1 finding from 1 review
Total mortality · people with primary hypertension
It is very uncertain whether combination with potassium‐sparing diuretics changes total mortality compared with monotherapy (very low certainty).
1 finding from 1 review
Cardiovascular mortality · people with primary hypertension
1 finding from 1 review
Cardiovascular events · people with primary hypertension
It is very uncertain whether combination with potassium‐sparing diuretics changes cardiovascular events compared with monotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · people with primary hypertension
It is very uncertain whether combination with potassium‐sparing diuretics changes serious adverse events compared with monotherapy (very low certainty).
1 finding from 1 review
Acute life‐threatening events · newborn infants with unconjugated hyperbilirubinaemia
1 finding from 1 review
Patient satisfaction · newborn infants with unconjugated hyperbilirubinaemia
1 finding from 1 review
Any breastfeeding at hospital discharge · newborn infants with unconjugated hyperbilirubinaemia
1 finding from 1 review
Decline in bilirubin (first measurement) · newborn infants with unconjugated hyperbilirubinaemia
1 finding from 1 review
Exchange transfusion · newborn infants with unconjugated hyperbilirubinaemia
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib probably leads to higher progression‐free survival(absolute effect size estimates based on… compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (moderate certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib showed no clear difference in serious adverse events (Grade 3 or 4) compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (low certainty).
1 finding from 1 review
Health‐related quality of life4 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib probably leads to higher progression‐free survival(absolute effect size estimates based on… compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (moderate certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib probably leads to higher overall survival (absolute effect size estimates based on survival… compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (moderate certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib showed no clear difference in serious adverse events (Grade 3 or 4) compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (low certainty).
1 finding from 1 review
Health‐related quality of life4 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib may leads to higher progression‐free survival(absolute effect size estimates based on… compared with atezolizumab + bevacizumab (targeted agent versus immunotherapy +… (low certainty).
1 finding from 1 review